PLB1004 + platinum-based chemotherapy

This is a **combination therapy** of **PLB1004**, a mono-aniline-pyrimidine **small molecule tyrosine kinase inhibitor (TKI)** targeting the epidermal growth factor receptor (**EGFR**), with a **platinum-based chemotherapy** regimen (which typically includes agents such as cisplatin or carboplatin). This combination is specifically under clinical investigation for the treatment of patients with **EGFR mutation-positive non-small cell lung cancer (NSCLC)**, particularly those with **EGFR exon 20 insertion mutations**. The aim of the combination is to improve efficacy and delay or overcome resistance that commonly develops with EGFR-TKI monotherapy. PLB1004 acts by inhibiting EGFR tyrosine kinase activity, while platinum agents induce DNA crosslinking leading to apoptosis in rapidly dividing tumor cells.

Brand names

Andamertinib

Other names

PLB1004 + platinum-based chemotherapyandamertinib + chemotherapyPLB1004 Plus ChemotherapyPLB-1004 Plus ChemotherapyPLB 1004 Plus Chemotherapy